Great Lakes Advisors LLC Makes New Investment in Bristol Myers Squibb Company $BMY

Great Lakes Advisors LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 192,181 shares of the biopharmaceutical company’s stock, valued at approximately $11,073,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Swiss RE Ltd. purchased a new position in shares of Bristol Myers Squibb in the fourth quarter worth about $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth about $25,000. Physician Wealth Advisors Inc. raised its position in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares during the period. Bayban purchased a new stake in Bristol Myers Squibb in the fourth quarter valued at $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb in the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 2.2%

BMY opened at $66.07 on Wednesday. The business has a fifty day moving average price of $59.94 and a 200 day moving average price of $59.14. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.10. The stock has a market capitalization of $134.97 billion, a price-to-earnings ratio of 14.55, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter last year, the business posted $1.46 EPS. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Wells Fargo & Company set a $65.00 target price on Bristol Myers Squibb and gave the company an “equal weight” rating in a research report on Friday, July 31st. Raymond James Financial initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Cantor Fitzgerald reiterated a “neutral” rating and set a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.